Abstract
Background The past two decades have witnessed reductions in time to diagnosis and reperfusion therapy in patients with ST elevation myocardial infarction (STEMI), largely through improvements in STEMI systems of care. While studies have demonstrated important benefits of timely coronary reperfusion in STEMI patients, those with non-system reasons for delay (NSD) are often excluded from these analyses, limiting insights into the overall quality of care for these patients.
Methods We analyzed the NSD in patients with STEMI undergoing primary PCI who were enrolled in the GWTD-CAD registry from January 1st, 2019, to December 31st, 2021. We examined the patient-level characteristics and outcomes for patients with and without reported NSD. We performed multivariable logistic regression models to examine the association between NSD and in-hospital mortality, adjusting for patient demographics, clinical variables, and social factors. We then categorized hospitals into four groups based on proportion of STEMI patients with NSD and examined the hospital-level characteristics across the quartiles. We further grouped hospitals by quality metric achievement of timely coronary reperfusion and examined the rates of NSD and treatment times for each category of achievement of the quality metric.
Results 74,372 patients were included in the study. 17,741 (23.9%) patients were reported to have NSD. Patients with NSD were older, and more likely to be female, of Black race, and have significant comorbidities including higher rates of cardiac arrest, heart failure and cardiogenic shock on presentation. In-hospital mortality rate was significantly higher in patients with NSD (15.4% vs 2.7%), (Adjusted OR 2.78, [95% CI:2.54-3.04]). Although high-achieving hospitals (those meeting the metrics ≥75%) excluded more patients, they consistently maintained shorter treatment times, even when NSD patients were included in the analysis.
Conclusion NSD in STEMI care is prevalent and linked to higher in-hospital mortality. While concerns about selective case exclusion exist, high-achieving hospitals consistently demonstrated excellent time-to-treatment even when patients with NSD are included.
Competing Interest Statement
The authors have declared no competing interest.
Clinical Trial
This is not a prospective study
Funding Statement
The Get With The Guidelines®?Coronary Artery Disease (GWTG-CAD) program is provided by the American Heart Association. GWTG-CAD is sponsored, in part, by Novartis, Novo Nordisk and Bayer.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Because data were used primarily at the local site for quality improvement, each participating hospital received either human research approval to enroll cases without individual patient consent under the common rule, or a waiver of authorization and exemption from subsequent review by their institutional review board (IRB). Advarra, the IRB for the American Heart Association, determined that this study is exempt from IRB oversight.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
The Precision Medicine Platform is a cloud-based system that allows researchers to collaborate and analyze large datasets from any computer in the world using a secure environment and the power of machine learning. Within the research interface, users have access to assorted datasets, including the industry-changing Get With The Guidelines® registry data to accelerate findings into impactful discoveries. Researchers must have an approved research proposal to access Get With The Guidelines® registry data.
https://www.heart.org/en/professional/quality-improvement/get-with-the-guidelines
